Mirae Asset Global Investments
MRNA icon

Mirae Asset Global Investments’s Moderna MRNA Stock Holding History

Mirae Asset Global Investments’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Buy
94,911
+7,595
+9% +$393K 0.01% 536
2026
Q1 		$4.44M Buy
87,316
+10,133
+13% +$473K ﹤0.01% 580
2025
Q4 		$2.28M Buy
77,183
+12,144
+19% +$330K 0.01% 761
2025
Q3 		$1.68M Buy
65,039
+6,366
+11% +$178K 0.01% 787
2025
Q2 		$1.62M Buy
58,673
+6,645
+13% +$175K 0.01% 748
2025
Q1 		$1.62M Buy
52,028
+6,207
+14% +$220K 0.01% 728
2024
Q4 		$1.84M Sell
45,821
-55,413
-55% -$2.65M 0.01% 686
2024
Q3 		$6.66M Buy
101,234
+18,750
+23% +$1.72M 0.03% 360
2024
Q2 		$10M Sell
82,484
-298,938
-78% -$37.8M 0.05% 251
2024
Q1 		$52.1M Sell
381,422
-26,668
-7% -$2.69M 0.11% 181
2023
Q4 		$40.6M Sell
408,090
-1,333
-0.3% -$112K 0.08% 237
2023
Q3 		$42.3M Buy
409,423
+64,344
+19% +$7.18M 0.09% 208
2023
Q2 		$41.9M Sell
345,079
-21,143
-6% -$2.82M 0.09% 220
2023
Q1 		$56.2M Buy
366,222
+2,076
+0.6% +$342K 0.13% 166
2022
Q4 		$65.4M Sell
364,146
-10,835
-3% -$1.77M 0.17% 135
2022
Q3 		$44.3M Sell
374,981
-9,775
-3% -$1.48M 0.12% 190
2022
Q2 		$55M Buy
384,756
+63,498
+20% +$9.08M 0.14% 164
2022
Q1 		$55.3M Buy
321,258
+80,010
+33% +$13.5M 0.12% 196
2021
Q4 		$61.3M Buy
241,248
+44,320
+23% +$13M 0.13% 175
2021
Q3 		$75.8M Buy
196,928
+59,501
+43% +$21.9M 0.19% 116
2021
Q2 		$32.3M Buy
137,427
+28,762
+26% +$5.14M 0.09% 279
2021
Q1 		$14.2M Sell
108,665
-19,080
-15% -$2.76M 0.05% 423
2020
Q4 		$13.3M Buy
127,745
+20,075
+19% +$2.03M 0.05% 415
2020
Q3 		$7.62M Buy
107,670
+99,811
+1,270% +$6.96M 0.04% 458
2020
Q2 		$505K Buy
+7,859
New +$430K ﹤0.01% 1136
2020
Q1 		– Sell
-11,344
Closed -$222K – 1461
2019
Q4 		$222K Buy
+11,344
New +$201K ﹤0.01% 1416

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Mirae Asset Global Investments's MRNA Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Moderna (MRNA) stake by 8.7% in Q2 2026, buying an estimated $393K and bringing the position to 94,911 shares worth $6.65M. The position accounts for 0.01% of the portfolio, ranked #536.

Mirae Asset Global Investments first reported a position in MRNA in Q4 2019 and has held it in 26 quarters since. The position peaked at $75.8M in Q3 2021. 400 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Mirae Asset Global Investments held 94,911 shares of Moderna worth $6.65M as of Q2 2026.
  • Mirae Asset Global Investments bought 7,595 Moderna shares in Q2 2026, an estimated $393K.
  • Moderna made up 0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #536 holding.
  • Mirae Asset Global Investments first reported a position in Moderna in Q4 2019 and has held it in 26 quarters since.
  • Mirae Asset Global Investments's Moderna position peaked at $75.8M in Q3 2021.
  • 400 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.